Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

173.59 +2.95 (+1.73%)
Streaming Delayed Price Updated: 9:49 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗
Via Stocktwits
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Small Cap Revival: Could Rate Cuts Spark a Rebound in Smaller Companies?
As whispers of impending interest rate cuts grow louder from central banks worldwide, a new wave of optimism is beginning to ripple through the often-overlooked small-cap sector. These nimble,... 
Via MarketMinute
Topics Economy
News headline image
Biotech Sector May Flip to Market Leader by Year-End ↗
As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter. 
Via MarketBeat
Topics ETFs Economy Stocks
CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit ↗
Via Stocktwits
CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back ↗
Via Stocktwits
News headline image
Major Sector ETFs Wildcard: Biotechnology ↗
On the weekly chart, IBB is breaking under the 200-week moving average. 
Via Talk Markets
Topics ETFs
News headline image
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
News headline image
FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market ↗
The FDA had already been investigating two earlier deaths linked to Elevidys. 
Via Stocktwits
Topics Death
News headline image
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn ↗
President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs ↗
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
News headline image
US Supreme Court Reportedly Upholds Part Of Obamacare That Guarantees Health Insurers Cover Preventive Care ↗
The Obamacare law requires health insurers to provide preventive care, including cancer screenings and HIV prevention medication, at no cost to patients. 
Via Stocktwits
Topics Government Lawsuit Religion
News headline image
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment ↗
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
News headline image
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns ↗
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
News headline image
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
The Major Sector ETFs Got Their Story ↗
XRT has more work to do. At best, the consumer sector is trying to bottom. At worst, this is a rally into resistance. 
Via Talk Markets
Topics ETFs
News headline image
Major Sector ETFs Break For Easter ↗
SMH holds steadfast above the 200-WMA even in the face of the tariffs and chip ban to China. 
Via Talk Markets
Topics Cryptocurrencies ETFs World Trade
News headline image
RFK Jr.'s Massive Federal Health Workforce Cut Could Take 'Decades To Rebuild,' Warn Experts: 'We Cannot Accurately Assess Whether We Are Truly Making America Healthier' ↗
Experts raise alarms about Health Secretary Robert F. Kennedy Jr's decision to layoff tens of thousands of federal workers, disrupting critical health data collection and research efforts. 
Via Benzinga
Topics Workforce
News headline image
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger ↗
Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma. 
Via Stocktwits
News headline image
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw? ↗
The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss. 
Via Stocktwits
News headline image
Can Buying In The Broader Market Pick Up Steam? ↗
Both SPY and QQQ must get back over and close above their 50-WMA to convince bulls the move Friday, while a reversal in the works, is not just a dead cat bounce. 
Via Talk Markets
Topics ETFs
News headline image
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic ↗
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. 
Via Stocktwits
News headline image
Healthcare Sector Trying To Bounce Back ↗
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
March Came In Like A Lion - Key Sectors Are Looking For A Lamb ↗
Looking at the monthly chart, XRT now sits back in economic contraction, or below the 23-month moving average. 
Via Talk Markets
Topics ETFs
News headline image
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential ↗
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027. 
Via Stocktwits
News headline image
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? ↗
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Biotech Rally Coming In Weeks Ahead? ↗
Large cap biopharma and MedTech stocks are leading the healthcare sector higher. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Semiconductors Fail A Key Support Level - And More ↗
It has been 2 years and 2 months since the ETF for Semiconductors SMH has traded below the 50-week moving average. 
Via Talk Markets
Topics ETFs
News headline image
4 Sectors That Thrive When Inflation Runs Hot
Sticky inflation and higher-for-longer interest rates is causing a rotation out of technology stocks, here are four sectors for investors hunting for value 
Via MarketBeat
Topics Economy World Trade
News headline image
PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? ↗
The rally follows PepGen's release of early clinical data from its Phase 1 trial evaluating its therapy to treat a rare genetic disorder. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.